<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39450093</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-494X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</Title><ISOAbbreviation>Antimicrob Steward Healthc Epidemiol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 anti-N antibodies among healthcare personnel without previous known COVID-19.</ArticleTitle><Pagination><StartPage>e184</StartPage><MedlinePgn>e184</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e184</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/ash.2024.389</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To measure SARS-CoV-2 anti-nucleocapsid (anti-N) antibody seropositivity among healthcare personnel (HCP) without a history of COVID-19 and to identify HCP characteristics associated with seropositivity.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Prospective cohort study from September 22, 2020, to March 3, 2022.</AbstractText><AbstractText Label="SETTING" NlmCategory="UNASSIGNED">A tertiary care academic medical center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="UNASSIGNED">727 HCP without prior positive SARS-CoV-2 PCR testing were enrolled; 559 HCP successfully completed follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">At enrollment and follow-up 1-6 months later, HCP underwent SARS-CoV-2 anti-N testing and were surveyed on demographics, employment information, vaccination status, and COVID-19 symptoms and exposures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 727 HCP enrolled, 27 (3.7%) had a positive SARS-CoV-2 anti-N test at enrollment. Seropositive HCPs were more likely to have a household exposure to COVID-19 in the past 30 days (OR 7.92, 95% CI 2.44-25.73), to have had an illness thought to be COVID-19 (4.31, 1.94-9.57), or to work with COVID-19 patients more than half the time (2.09, 0.94-4.77). Among 559 HCP who followed-up, 52 (9.3%) had a positive SARS-CoV-2 anti-N antibody test result. Seropositivity at follow-up was associated with community/household exposures to COVID-19 within the past 30 days (9.50, 5.02-17.96; 2.90, 1.31-6.44), having an illness thought to be COVID-19 (8.24, 4.44-15.29), and working with COVID-19 patients more than half the time (1.50, 0.80-2.78).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Among HCP without prior positive SARS-CoV-2 testing, SARS-CoV-2 anti-N seropositivity was comparable to that of the general population and was associated with COVID-19 symptomatology and both occupational and non-occupational exposures to COVID-19.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tiwary</LastName><ForeName>Sajal</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0004-2213-5755</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neil</LastName><ForeName>Caroline A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-2966-0750</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peacock</LastName><ForeName>Kate</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2379-0335</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cass</LastName><ForeName>Candice</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amor</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Meghan A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arter</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarado</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogt</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials><Identifier Source="ORCID">0000-0001-6251-0733</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burnham</LastName><ForeName>Carey-Ann D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farnsworth</LastName><ForeName>Christopher W</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0001-7169-3850</Identifier><AffiliationInfo><Affiliation>Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Jennie H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-7824-6276</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CDC Prevention Epicenters Program</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antimicrob Steward Healthc Epidemiol</MedlineTA><NlmUniqueID>9918266096106676</NlmUniqueID><ISSNLinking>2732-494X</ISSNLinking></MedlineJournalInfo><CoiStatement>C.W.F. has received grants or contracts from Abbott Laboratories, Roche Diagnostics, Beckman Coulter, Qiagen, Cepheid, Sebia, The Binding Site, and Siemens; consulting fees from Roche, Abbott Laboratories, Biorad, Cytovale, and Siemens; honoraria and meeting support from AACC; and has a leadership role on the Clinical Chemistry Editorial Board. V.J.F. has received grants or contracts from the Foundation for Barnes-Jewish Hospital, the Doris Duke Charitable Foundation, and the National Center for Advancing Translational Science (NIH); royalties or licenses from Elsevier; has had a leadership role in the Infectious Diseases Society of America; and reports other financial or non-financial interests in Cigna/Express-Scripts. C.D.B. has received grants or contracts from Cepheid, bioMerieux, and Biofire; consulting fees from Pattern Bioscience, Roche, Cepheid, and Beckman Coulter; honoraria from Roche and bioMerieux; meeting support from the American Society for Microbiology and AACC; and has stock or stock options in Pattern Bioscience. J.H.K. has received additional support for this work from the National Institute of Allergy and Infectious Diseases (NIH). All other authors report no potential conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39450093</ArticleId><ArticleId IdType="pmc">PMC11500274</ArticleId><ArticleId IdType="doi">10.1017/ash.2024.389</ArticleId><ArticleId IdType="pii">S2732494X24003899</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Heal 2020;5:e475–e483. doi: 10.1016/S2468-2667(20)30164-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30164-X</ArticleId><ArticleId IdType="pmc">PMC7491202</ArticleId><ArticleId IdType="pubmed">32745512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholami M, Fawad I, Shadan S, et al. COVID-19 and healthcare workers: a systematic review and meta-analysis. Int J Infect Dis 2021;104:335–346. doi: 10.1016/j.ijid.2021.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.01.013</ArticleId><ArticleId IdType="pmc">PMC7798435</ArticleId><ArticleId IdType="pubmed">33444754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Soe MM, Konnor R, et al. Hospital capacities and shortages of healthcare resources among US hospitals during the coronavirus disease 2019 (COVID-19) pandemic, National Healthcare Safety Network (NHSN), March 27-July 14, 2020. Infect Control Hosp Epidemiol 2022;43:1473–1476. doi: 10.1017/ice.2021.280</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2021.280</ArticleId><ArticleId IdType="pmc">PMC8280389</ArticleId><ArticleId IdType="pubmed">34167599</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas M, Zhu NJ, Mookerjee S, et al. Hospital-onset COVID-19 infection surveillance systems: a systematic review. J Hosp Infect 2021;115:44–50. doi: 10.1016/j.jhin.2021.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2021.05.016</ArticleId><ArticleId IdType="pmc">PMC8278304</ArticleId><ArticleId IdType="pubmed">34098049</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet (London, England) 2022;399:1618–1624. doi: 10.1016/S0140-6736(22)00327-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mathieu E, Ritchie H, Rodés-Guirao L, et al.
Coronavirus Pandemic (COVID-19). Oxford, England: University of Oxford. OurWorldInData.org.</Citation></Reference><Reference><Citation>Klompas M, Pandolfi MC, Nisar AB, Baker MA, Rhee C. Association of omicron vs Wild-type SARS-CoV-2 variants with hospital-onset SARS-CoV-2 infections in a US regional hospital system. JAMA 2022;328:296–298. doi: 10.1001/jama.2022.9609</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.9609</ArticleId><ArticleId IdType="pmc">PMC9201738</ArticleId><ArticleId IdType="pubmed">35704347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S-C, Chan VW-M, Yuen LL-H, et al. Infection of healthcare workers despite a high vaccination rate during the fifth wave of COVID-19 due to Omicron variant in Hong Kong. Infect Prev Pract 2023;5:100261. doi: 10.1016/j.infpip.2022.100261</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infpip.2022.100261</ArticleId><ArticleId IdType="pmc">PMC9705264</ArticleId><ArticleId IdType="pubmed">36465098</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilchuk V, Arrandale VH, Armstrong J. Potential risk factors associated with COVID-19 in health care workers. Occup Med (Chic Ill) 2022;72:35–42. doi: 10.1093/occmed/kqab148</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqab148</ArticleId><ArticleId IdType="pmc">PMC8689909</ArticleId><ArticleId IdType="pubmed">34729600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins LPA, Pallett SJC, Mazzella A, et al. Transmission dynamics and associated mortality of nosocomial COVID-19 throughout 2021: a retrospective study at a large teaching hospital in London. J Hosp Infect 2023;133:62–69. doi: 10.1016/j.jhin.2022.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2022.12.014</ArticleId><ArticleId IdType="pmc">PMC9827730</ArticleId><ArticleId IdType="pubmed">36632897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:19–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldman SE, Buehring T, Escobar DJ, et al. secondary cases of delta variant Coronavirus Disease 2019 among vaccinated healthcare workers with breakthrough infections is rare. Clin Infect Dis 2022;75:E895–E897. doi: 10.1093/cid/ciab916</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab916</ArticleId><ArticleId IdType="pmc">PMC8574310</ArticleId><ArticleId IdType="pubmed">34694358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan S, Khan SR, Deliwala S, et al. Postvaccination SARS-CoV-2 infection among healthcare workers: a systematic review and meta-analysis. J Med Virol 2022;94:1428–1441. doi: 10.1002/jmv.27457</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27457</ArticleId><ArticleId IdType="pmc">PMC8661690</ArticleId><ArticleId IdType="pubmed">34783055</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–2615. doi: 10.1056/nejmoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohil SK, Olenslager K, Quan KA, et al. Asymptomatic and symptomatic COVID-19 infections among health care personnel before and after vaccination. JAMA Netw Open 2021;4:2021–2024. doi: 10.1001/jamanetworkopen.2021.15980</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.15980</ArticleId><ArticleId IdType="pmc">PMC8267609</ArticleId><ArticleId IdType="pubmed">34236414</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan PD, Hall VJ, Foulkes S, et al. Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort. Lancet Reg Heal Eur 2024;36:1–12. doi: 10.1016/j.lanepe.2023.100809</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100809</ArticleId><ArticleId IdType="pmc">PMC10727938</ArticleId><ArticleId IdType="pubmed">38111727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hönning A, Tomczyk S, Hermes J, et al. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination. BMC Infect Dis 2024;24:1–12. doi: 10.1186/s12879-024-09338-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09338-5</ArticleId><ArticleId IdType="pmc">PMC11040945</ArticleId><ArticleId IdType="pubmed">38658874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouquet M, Decarreaux D, Di Domenico L, et al. SARS-CoV-2 infection prevalence and associated factors among primary healthcare workers in France after the third COVID-19 wave. Sci Rep 2024;14:1–12. doi: 10.1038/s41598-024-55477-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55477-9</ArticleId><ArticleId IdType="pmc">PMC10914718</ArticleId><ArticleId IdType="pubmed">38443618</ArticleId></ArticleIdList></Reference><Reference><Citation>Baymon DME, Vakkalanka JP, Krishnadasan A, et al. Race, ethnicity, and delayed time to COVID-19 testing among us health care workers. JAMA Netw open 2024;7:e245697. doi: 10.1001/jamanetworkopen.2024.5697</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.5697</ArticleId><ArticleId IdType="pmc">PMC11007575</ArticleId><ArticleId IdType="pubmed">38598239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci U S A 2021;118:1–12. doi: 10.1073/pnas.2109229118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109229118</ArticleId><ArticleId IdType="pmc">PMC8403749</ArticleId><ArticleId IdType="pubmed">34376550</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open 2021;4:4–11. doi: 10.1001/jamanetworkopen.2020.35057</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.35057</ArticleId><ArticleId IdType="pmc">PMC7791354</ArticleId><ArticleId IdType="pubmed">33410879</ArticleId></ArticleIdList></Reference><Reference><Citation>
The Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing Key Points: Introduction to COVID-19 Antibodies. 2022. Atlanta, Georgia, USA: Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html#print.</Citation></Reference><Reference><Citation>Bosserman RE, Farnsworth CW, O’Neil CA, et al. Antibodies in healthcare personnel following severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection. Antimicrob Steward Healthc Epidemiol 2022;2:1–4. doi: 10.1017/ash.2022.231</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.231</ArticleId><ArticleId IdType="pmc">PMC9726486</ArticleId><ArticleId IdType="pubmed">36483363</ArticleId></ArticleIdList></Reference><Reference><Citation>Angel Y, Spitzer A, Henig O, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA 2021;325:2457–2465. doi: 10.1001/jama.2021.7152</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7152</ArticleId><ArticleId IdType="pmc">PMC8220476</ArticleId><ArticleId IdType="pubmed">33956048</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of messenger RNA Coronavirus disease 2019 (COVID19) vaccines against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection in a cohort of healthcare personnel. Clin Infect Dis 2021;73:E1376–E1379. doi: 10.1093/cid/ciab361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab361</ArticleId><ArticleId IdType="pmc">PMC8135611</ArticleId><ArticleId IdType="pubmed">33900384</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Guo Y, Zhang S, Kong Y, Shen Z, Zhang J. Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 omicron variant: a systematic review and analysis. J Med Virol 2022;94:5790–5801. doi: 10.1002/jmv.28066</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28066</ArticleId><ArticleId IdType="pmc">PMC9538850</ArticleId><ArticleId IdType="pubmed">35961786</ArticleId></ArticleIdList></Reference><Reference><Citation>Goss CW, Maricque BB, Anwuri V V., et al. SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County. Ann Epidemiol 2022;71:31–37. doi: 10.1016/j.annepidem.2022.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2022.03.002</ArticleId><ArticleId IdType="pmc">PMC8902054</ArticleId><ArticleId IdType="pubmed">35276338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant — national healthcare safety network, March 1–August. MMWR Morb Mortal Wkly Rep 2021;70:1163–1166. doi: 10.15585/mmwr.mm7034e3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7034e3</ArticleId><ArticleId IdType="pmc">PMC8389386</ArticleId><ArticleId IdType="pubmed">34437519</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 2022;22:183–195. doi: 10.1016/S1473-3099(21)00648-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Eales O, de Oliveira Martins L, Page AJ, et al. Dynamics of competing SARS-CoV-2 variants during the omicron epidemic in England. Nat Commun 2022;13:1–11. doi: 10.1038/s41467-022-32096-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32096-4</ArticleId><ArticleId IdType="pmc">PMC9330949</ArticleId><ArticleId IdType="pubmed">35902613</ArticleId></ArticleIdList></Reference><Reference><Citation>The Centers for Disease Control and Prevention. COVID-19 SeroHub. COVID-19 Seroprevalence Studies Hub. Atlanta, Georgia, USA: Centers for Disease Control and Prevention.</Citation></Reference><Reference><Citation>Iversen K, Kristensen JH, Hasselbalch RB, et al. Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers. Clin Microbiol Infect 2022;28:710–717. doi: 10.1016/j.cmi.2021.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.005</ArticleId><ArticleId IdType="pmc">PMC8447554</ArticleId><ArticleId IdType="pubmed">34543759</ArticleId></ArticleIdList></Reference><Reference><Citation>Althoff A, Papasavas P, Olugbile S, et al. Factors affecting seroreversion by 6 months among healthcare workers in connecticut. J Hosp Infect 2022;121:132–133. doi: 10.1016/j.jhin.2021.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2021.12.001</ArticleId><ArticleId IdType="pmc">PMC8654735</ArticleId><ArticleId IdType="pubmed">34896408</ArticleId></ArticleIdList></Reference><Reference><Citation>Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network — 12 states, April–August 2020. MMWR Morb Mortal Wkly Rep 2020;69:1762–1766. doi: 10.15585/mmwr.mm6947a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6947a2</ArticleId><ArticleId IdType="pmc">PMC7727600</ArticleId><ArticleId IdType="pubmed">33237893</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JM, Nakayama JY, Hegarty MO, Mcgowan A, Teran RA. SARS-CoV-2 B. 1. 1. 529 (omicron) variant transmission within households —. MMWR Morb Mortal Wkly Rep 2022;71:1–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893332</ArticleId><ArticleId IdType="pubmed">35238860</ArticleId></ArticleIdList></Reference><Reference><Citation>Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw Open 2022;5:E229317. doi: 10.1001/jamanetworkopen.2022.9317</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.9317</ArticleId><ArticleId IdType="pmc">PMC9051991</ArticleId><ArticleId IdType="pubmed">35482308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JH, Budge PJ, O’Neil CA, et al. Clinical and occupational risk factors for coronavirus disease 2019 (COVID-19) in healthcare personnel. Antimicrob Steward Healthc Epidemiol 2022;2:1–8. doi: 10.1017/ash.2022.250</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.250</ArticleId><ArticleId IdType="pmc">PMC9727206</ArticleId><ArticleId IdType="pubmed">36505949</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev 2020;2020: 1–55. doi: 10.1002/14651858.CD013718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013718</ArticleId><ArticleId IdType="pmc">PMC8453488</ArticleId><ArticleId IdType="pubmed">33502003</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan A, Steinberg E, Fries JA, et al. Estimating the efficacy of symptom-based screening for COVID-19. npj Digit Med 2020;3:8–10. doi: 10.1038/s41746-020-0300-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-0300-0</ArticleId><ArticleId IdType="pmc">PMC7359358</ArticleId><ArticleId IdType="pubmed">32695885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022;386:1207–1220. doi: 10.1056/nejmoa2118691</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>